The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
Patient with suspicion of localised thymic epithelial tumour.
Age ≥ 18 years.
Treatment-naïve patient for this disease.
Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
Neoadjuvant chemotherapy.
No social security affiliation.
Person under legal protection.
Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).